Insmed Trading Volume Surges 278.94% Ranking 70th in Market Activity

On April 25, 2025, Insmed's trading volume reached 9.35 billion, marking a significant increase of 278.94% compared to the previous day, ranking 70th in the day's stock market activity. Insmed (INSM) closed the day with a 1.06% gain.

Insmed Incorporated, a biopharmaceutical company, has recently announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Treprostinil Inhalation Solution. The CRL indicates that the FDA is unable to approve the application in its current form, citing the need for additional clinical data to support the safety and efficacy of the drug. Insmed has stated that it is currently reviewing the CRL and will work with the FDA to address the concerns raised.

In other news, Insmed has also announced that it has entered into a strategic collaboration with a leading global pharmaceutical company to develop and commercialize a new therapeutic for the treatment of pulmonary arterial hypertension (PAH). The collaboration will leverage the strengths of both companies to accelerate the development of the new therapy and bring it to patients in need as quickly as possible. The terms of the collaboration were not disclosed.

Additionally, Insmed has reported positive results from a Phase 2 clinical trial of its investigational drug, INS-1009, for the treatment of non-cystic fibrosis bronchiectasis. The trial met its primary endpoint, demonstrating a statistically significant improvement in lung function compared to placebo. The company plans to initiate a Phase 3 trial of INS-1009 in the second half of 2025.